{
    "2018-07-24": [
        [
            {
                "time": "2018-07-25",
                "original_text": "What to Expect from Edwards Lifesciences’ Q2 2018 Results",
                "features": {
                    "keywords": [
                        "Edwards Lifesciences",
                        "Q2",
                        "Results"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-25",
                "original_text": "Is a Beat in the Cards for AbbVie (ABBV) in Q2 Earnings?",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Q2",
                        "Earnings"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-25",
                "original_text": "Why Most Analysts Are Bullish on Baxter International",
                "features": {
                    "keywords": [
                        "Analysts",
                        "Bullish",
                        "Baxter International"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-25",
                "original_text": "Novartis’s Q2 2018 Earnings: Alcon",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Q2",
                        "Earnings",
                        "Alcon"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-25",
                "original_text": "What Drove Growth for J&J’s Medical Device Business?",
                "features": {
                    "keywords": [
                        "Growth",
                        "J&J",
                        "Medical Device"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-25",
                "original_text": "Pharma/Biotech Stock Q2 Earnings on Jul 25: GILD, VRTX & GSK",
                "features": {
                    "keywords": [
                        "Pharma",
                        "Biotech",
                        "Stock",
                        "Q2",
                        "Earnings",
                        "GILD",
                        "VRTX",
                        "GSK"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-25",
                "original_text": "The Zacks Analyst Blog Highlights: Johnson & Johnson, Nike, Schlumberger, CSX and Intuitive Surgical",
                "features": {
                    "keywords": [
                        "Zacks",
                        "Analyst",
                        "Blog",
                        "Johnson & Johnson",
                        "Nike",
                        "Schlumberger",
                        "CSX",
                        "Intuitive Surgical"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "consumer goods",
                        "energy",
                        "transportation",
                        "technology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-25",
                "original_text": "Analysts’ Targets and Recommendations for Amgen Stock",
                "features": {
                    "keywords": [
                        "Analysts",
                        "Targets",
                        "Recommendations",
                        "Amgen",
                        "Stock"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-25",
                "original_text": "J&J’s Oncology Franchise Saw 42.2% Growth in Q2 2018",
                "features": {
                    "keywords": [
                        "J&J",
                        "Oncology",
                        "Franchise",
                        "Growth",
                        "Q2",
                        "2018"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-25",
                "original_text": "GSK JV ViiV Healthcare Presents Data From Two Phase III Studies",
                "features": {
                    "keywords": [
                        "GSK",
                        "JV",
                        "ViiV",
                        "Healthcare",
                        "Data",
                        "Phase III",
                        "Studies"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}